Last reviewed · How we verify

NCT00227656

Phase II Trial of Capecitabine (Xeloda®) and Pegylated Interferon Alfa-2A(Pegasys®) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma

Terminated Phase 2 Last updated 10 December 2012
What this trial tests

Phase 2 trial testing PEG-interferon alfa-2a in Breast Cancer in 2 participants. Terminated before completion.

Timeline
1 September 2005
Primary endpoint
1 November 2006
1 November 2006

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment2
Start date1 September 2005
Primary completion1 November 2006
Estimated completion1 November 2006
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Breast Cancer or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pegylated interferon alfa-2a may interfere with the growth of tumor cells. Giving capecitabine together with pegylated interferon alfa-2a may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving capecitabine together with pegylated interferon alfa-2a works in treating patients with recurrent or progressive brain metastases due to breast cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
    Shah N, Mohammad AS, Saralkar P, Sprowls SA, et al · · 2018 · cited 102× · PMID 29604436 · DOI 10.1016/j.phrs.2018.03.021
  2. Double-edged effects of interferons on the regulation of cancer-immunity cycle.
    Zhang X, Wang S, Zhu Y, Zhang M, et al · · 2021 · cited 54× · PMID 34262796 · DOI 10.1080/2162402x.2021.1929005
  3. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
    Ye Y, Xu C, Chen F, Liu Q, et al · · 2021 · cited 19× · PMID 34899721 · DOI 10.3389/fimmu.2021.771201
  4. Immune therapy for breast cancer in 2010-hype or hope?
    Florescu A, Amir E, Bouganim N, Clemons M. · · 2011 · cited 19× · PMID 21331271 · DOI 10.3747/co.v18i1.623
  5. Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases.
    Carney CP, Pandey N, Kapur A, Woodworth GF, et al · · 2021 · cited 15× · PMID 34716900 · DOI 10.1007/s13346-021-01039-9
  6. Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview.
    Kotecha R, La Rosa A, Brown PD, Vogelbaum MA, et al · · 2025 · cited 6× · PMID 39495010 · DOI 10.1093/neuonc/noae220

Verify or expand the search:

Other trials of PEG-interferon alfa-2a

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00227656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing